Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer
Dr. Basi joins Sarepta after serving in several senior leadership roles at Elan, including chief science and technology officer and head of pre-clinical development. He was also the former CSO for
“Dr. Basi brings to Sarepta a long and impressive career marked by a commitment to scientific excellence,” said Mr. Ingram. “I am excited to bring Dr. Basi to the team as we focus on accelerating our pipeline. We have made strides toward our goal of bringing therapies and a better life to as many children with Duchenne muscular dystrophy as possible, but patients are waiting and we must accelerate our efforts. Dr. Basi’s expertise will prove invaluable as we move our next-generation technology into the clinic and continue to support and advance our exciting collaborative programs.”
“The scientific underpinnings of Sarepta’s technology for the development of precision genetic medicines are unparalleled in the industry. I am particularly excited about the Company’s PMO and PPMO technology platforms, and our gene therapy investments, which have the potential to generate a strong pipeline of unique treatments for DMD and other neuromuscular diseases,” said Dr. Basi. “With a multi-front treatment approach, Sarepta is poised to make a profound difference in the lives of patients with rare neuromuscular diseases and their families. I am excited to join Sarepta, and its strong team of scientists, as we focus on realizing the potential of our existing pipeline while exploring additional opportunities to bolster our pipeline to improve the lives of those suffering from rare diseases.”
Dr. Basi earned his Ph.D. in Biochemistry from the
About Sarepta Therapeutics
This press release contains "forward-looking statements". Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regardingthe appointment of Dr. Basi strengthening Sarepta’s leadership team as it accelerates the advancement of its rare disease pipeline; Sarepta’s goal of bringing therapies and a better life to as many children with DMD as possible;Dr. Basi’s expertise proving invaluable as Sarepta movesits next-generation technology into the clinic and continues to support and advance its collaborative programs; the scientific underpinnings of Sarepta’s technology for the development of precision genetic medicines and the potential of Sarepta’s PMO and PPMO technology platforms, and its gene therapy investments, to generate a strong pipeline of unique treatments for DMD and other neuromuscular diseases; and Sarepta being poised to make a profound difference in the lives of patients with rare neuro-muscular diseases and their families.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Known risk factors include, among others: Sarepta may not be able to successfully harness its technologies, including its PMO and PPMO platforms, to achieve its goals; Sarepta may not be able to develop and commercialize additional novel therapies that address DMD or rapidly advance its RNA-targeted platforms and gene therapy programs; Sarepta may not be able to complete clinical trials required by the
Any of the foregoing risks could adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2016 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 filed with the
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics
Latest Annual Report( FY 2017 )
Sarepta IR Presentation (December 2017)